Your browser doesn't support javascript.
loading
The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy.
Vici, Patrizia; Mottolese, Marcella; Pizzuti, Laura; Barba, Maddalena; Sperati, Francesca; Terrenato, Irene; Di Benedetto, Anna; Natoli, Clara; Gamucci, Teresa; Angelucci, Domenico; Ramieri, Maria Teresa; Di Lauro, Luigi; Sergi, Domenico; Bartucci, Monica; Dattilo, Rosanna; Pagliuca, Alfredo; De Maria, Ruggero; Maugeri-Saccà, Marcello.
Afiliação
  • Vici P; Division of Medical Oncology B, Regina Elena National Cancer Institute, Rome, Italy. These authors contributed equally to this work.
  • Mottolese M; Department of Pathology, Regina Elena National Cancer Institute, Rome, Italy. These authors contributed equally to this work.
  • Pizzuti L; Division of Medical Oncology B, Regina Elena National Cancer Institute, Rome, Italy.
  • Barba M; Division of Medical Oncology B, Regina Elena National Cancer Institute, Rome, Italy. Scientific Direction, Regina Elena National Cancer Institute, Rome, Italy.
  • Sperati F; Biostatistics-Scientific Direction, Regina Elena National Cancer Institute, Rome, Italy.
  • Terrenato I; Biostatistics-Scientific Direction, Regina Elena National Cancer Institute, Rome, Italy.
  • Di Benedetto A; Department of Pathology, Regina Elena National Cancer Institute, Rome, Italy.
  • Natoli C; Department of Experimental and Clinical Sciences, University "G. d'Annunzio", Chieti, Italy.
  • Gamucci T; Medical Oncology Unit, ASL Frosinone, Frosinone, Italy.
  • Angelucci D; Division of Pathology, 'SS. Annunziata' Hospital, Chieti, Italy.
  • Ramieri MT; Division of Pathology, ASL Frosinone, Frosinone, Italy.
  • Di Lauro L; Division of Medical Oncology B, Regina Elena National Cancer Institute, Rome, Italy.
  • Sergi D; Division of Medical Oncology B, Regina Elena National Cancer Institute, Rome, Italy.
  • Bartucci M; Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
  • Dattilo R; Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
  • Pagliuca A; Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
  • De Maria R; Scientific Direction, Regina Elena National Cancer Institute, Rome, Italy.
  • Maugeri-Saccà M; Division of Medical Oncology B, Regina Elena National Cancer Institute, Rome, Italy. Scientific Direction, Regina Elena National Cancer Institute, Rome, Italy.
Oncotarget ; 5(20): 9619-25, 2014 Oct 30.
Article em En | MEDLINE | ID: mdl-25294813
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fatores de Transcrição / Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores Tumorais / Receptor ErbB-2 Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fatores de Transcrição / Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores Tumorais / Receptor ErbB-2 Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2014 Tipo de documento: Article